A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study

被引：0
作者：
Daniele, Bruno
Di Maio, Massimo
Gallo, Ciro
Gasbarrini, Antonio
Carteni, Giacomo
Di Costanzo, Giovan Giuseppe
Craxi, Antonio
Cabibbo, Giuseppe
Bolondi, Luigi
Granito, Alessandro
Missale, Gabriele
Frassoldati, Antonio
Angelico, Mario
Roselli, Mario
Daniele, Gennaro
Perrone, Francesco
机构：
[1] G Rummo Hosp, Benevento, Italy
[2] Natl Canc Inst, Clin Trials Unit, Naples, Italy
[3] Univ Naples 2, Naples, Italy
[4] Policlin Univ Agostino Gemelli, Rome, Italy
[5] Azienda Osped Rilievo Nazl A Cardarelli, Naples, Italy
[6] Azienda Osped Univ, Policlin Paolo Giaccone, Palermo, Italy
[7] Azienda Osped Univ Policlin St Orsola Malpighi, Bologna, Italy
[8] Azienda Osped Univ Parma, Parma, Italy
[9] Az Osped Univ Arcispedale St Anna Ferrara, Ferrara, Italy
[10] Azienda Osped Univ Policlin Tor Vergata, Rome, Italy
[11] Natl Canc Inst, Naples, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4151
引用
收藏
页数：1
相关论文
共 50 条
[41]   Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. [J].
Qin, Shukui ;
Fang, Weijia ;
Ren, ZhengGang ;
Shuangyan, Ou ;
Lim, Ho Yeong ;
Zhang, Feng ;
Choi, Hye Jin ;
Tong, Jiandong ;
Tao, Min ;
Xu, Aibing ;
Cheng, Ashley Chi Kin ;
Lu, Chang-Hsien ;
Chiu, Chang-Fang ;
Wahid, Mohamed Ibrahim A. ;
Kamble, Shital ;
Norquist, Josephine M. ;
Zhong, Wen Yan ;
Li, Chen ;
Chen, Zhendong .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[42]   Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone [J].
Kang, Jung Hun ;
Lee, Soon Il ;
Lim, Do Hyoung ;
Park, Keon-Woo ;
Oh, Sung Yong ;
Kwon, Hyuk-Chan ;
Hwang, In Gyu ;
Lee, Sang-Cheol ;
Nam, Eunmi ;
Shin, Dong Bok ;
Lee, Jeeyun ;
Park, Joon Oh ;
Park, Young Suk ;
Lim, Ho Yeong ;
Kang, Won Ki ;
Park, Se Hoon .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) :1513-1518
[43]   Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial [J].
Cainap, Calin ;
Qin, Shukui ;
Huang, Wen-Tsung ;
Chung, Ik Joo ;
Pan, Hongming ;
Cheng, Ying ;
Kudo, Masatoshi ;
Kang, Yoon-Koo ;
Chen, Pei-Jer ;
Toh, Han-Chong ;
Gorbunova, Vera ;
Eskens, Ferry A. L. M. ;
Qian, Jiang ;
McKee, Mark D. ;
Ricker, Justin L. ;
Carlson, Dawn M. ;
El-Nowiem, Saied .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) :172-U77
[44]   Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma [J].
Cheng, A. ;
Kang, Y. ;
Chen, Z. ;
Tsao, C. ;
Qin, S. ;
Kim, J. ;
Burock, K. ;
Zou, J. ;
Voliotis, D. ;
Guan, Z. Z. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[45]   Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial. [J].
Ikeda, Masafumi ;
Shimizu, Satoshi ;
Sato, Tosiya ;
Morimoto, Manabu ;
Inaba, Yoshitaka ;
Kojima, Yasushi ;
Hagihara, Atsushi ;
Kudo, Masatoshi ;
Nakamori, Shoji ;
Kaneko, Shuichi ;
Sugimoto, Rie ;
Tahara, Toshiyuki ;
Ohmura, Takumi ;
Yasui, Kohichiroh ;
Sato, Keiko ;
Ishii, Hiroshi ;
Furuse, Junji ;
Okusaka, Takuji .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[46]   A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC) [J].
Kuboki, Y. ;
Yoshino, T. ;
Yamazaki, K. ;
Nishina, T. ;
Komatsu, Y. ;
Baba, H. ;
Tsuji, A. ;
Yamaguchi, K. ;
Muro, K. ;
Ohtsu, A. .
EUROPEAN JOURNAL OF CANCER, 2011, 47 :S392-S392
[47]   The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17 [J].
Vickers, M. M. ;
Karapetis, C. S. ;
Tu, D. ;
O'Callaghan, C. J. ;
Price, T. J. ;
Tebbutt, N. C. ;
Van Hazel, G. ;
Shapiro, J. D. ;
Pavlakis, N. ;
Gibbs, P. ;
Blondal, J. ;
Lee, U. J. Yu Min ;
Meharchand, J. M. ;
Burkes, R. L. ;
Rubin, S. H. ;
Simes, J. ;
Zalcberg, J. R. ;
Moore, M. J. ;
Zhu, L. ;
Jonker, D. J. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[48]   LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies. [J].
Lenz, Heinz-Josef ;
Tabernero, Josep ;
Yoshino, Takayuki ;
Oum'Hamed, Zohra ;
Vlassak, Soetkin ;
Sassi, Mouna ;
Van Cutsem, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[49]   Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). [J].
Finn, Richard S. ;
Ryoo, Baek-Yeol ;
Merle, Philippe ;
Kudo, Masatoshi ;
Bouattour, Mohamed ;
Lim, Ho-Yeong ;
Breder, Valeriy Vladimirovich ;
Edeline, Julien ;
Chao, Yee ;
Ogasawara, Sadahisa ;
Yau, Thomas ;
Garrido, Marcelo ;
Chan, Stephen Lam ;
Knox, Jennifer J. ;
Daniele, Bruno ;
Ebbinghaus, Scot ;
Chen, Erluo ;
Siegel, Abby B. ;
Zhu, Andrew X. ;
Cheng, Ann-Lii .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[50]   LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies. [J].
Lenz, Heinz-Josef ;
Tabernero, Josep ;
Yoshino, Takayuki ;
Oum'Hamed, Zohra ;
Vlassak, Soetkin ;
Sassi, Mouna ;
Van Cutsem, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345